Literature DB >> 25865281

The mean lung dose (MLD) : predictive criterion for lung damage?

Thomas Herrmann1, Peter Geyer, Steffen Appold.   

Abstract

AIM: The purpose of this work was to prove the validity of the mean lung dose (MLD), widely used in clinical practice to estimate the lung toxicity of a treatment plan, by reevaluating experimental data from mini pigs.
MATERIALS AND METHODS: A total of 43 mini pigs were irradiated in one of four dose groups (25, 29, 33, and 37 Gy). Two regimens were applied: homogeneous irradiation of the right lung or partial irradiation of both lungs-including parts with lower dose-but with similar mean lung doses. The animals were treated with five fractions with a linear accelerator applying a CT-based treatment plan. The clinical lung reaction (breathing frequency) and morphological changes in CT scans were examined frequently during the 48 weeks after irradiation.
RESULTS: A clear dose-effect relationship was found for both regimens of the trial. However, a straightforward relationship between the MLD and the relative number of responders with respect to different grades of increased breathing frequency for both regimens was not found. A morphologically based parameter NTCPlung was found to be more suitable for this purpose. The dependence of this parameter on the MLD is markedly different for the two regimens.
CONCLUSION: In clinical practice, the MLD can be used to predict lung toxicity of a treatment plan, except for dose values that could lead to severe side effects. In the latter mentioned case, limitations to the predictive value of the MLD are possible. Such severe developments of a radiation-induced pneumopathy are better predicted by the NTCPlung formalism. The predictive advantage of this parameter compared to the MLD seems to remain in the evaluation and comparison of widely differing dose distributions, like in the investigated trial.

Entities:  

Mesh:

Year:  2015        PMID: 25865281     DOI: 10.1007/s00066-015-0833-3

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


  24 in total

1.  Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques.

Authors:  David A Palma; Suresh Senan; Cornelis J A Haasbeek; Wilko F A R Verbakel; Andrew Vincent; Frank Lagerwaard
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-26       Impact factor: 7.038

2.  Combining advanced radiotherapy technologies to maximize safety and tumor control probability in stage III non-small cell lung cancer.

Authors:  M Guckenberger; A Kavanagh; M Partridge
Journal:  Strahlenther Onkol       Date:  2012-08-31       Impact factor: 3.621

3.  Physiological interaction of heart and lung in thoracic irradiation.

Authors:  Ghazaleh Ghobadi; Sonja van der Veen; Beatrijs Bartelds; Rudolf A de Boer; Michael G Dickinson; Johan R de Jong; Hette Faber; Maarten Niemantsverdriet; Sytze Brandenburg; Rolf M F Berger; Johannes A Langendijk; Robert P Coppes; Peter van Luijk
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-09-11       Impact factor: 7.038

Review 4.  Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis.

Authors:  David A Palma; Suresh Senan; Kayoko Tsujino; Robert B Barriger; Ramesh Rengan; Marta Moreno; Jeffrey D Bradley; Tae Hyun Kim; Sara Ramella; Lawrence B Marks; Luigi De Petris; Larry Stitt; George Rodrigues
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-09       Impact factor: 7.038

5.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer.

Authors:  Wouter van Elmpt; Dirk De Ruysscher; Anke van der Salm; Annemarie Lakeman; Judith van der Stoep; Daisy Emans; Eugène Damen; Michel Öllers; Jan-Jakob Sonke; José Belderbos
Journal:  Radiother Oncol       Date:  2012-04-06       Impact factor: 6.280

6.  Impact of toxicity grade and scoring system on the relationship between mean lung dose and risk of radiation pneumonitis in a large cohort of patients with non-small cell lung cancer.

Authors:  Susan L Tucker; Hekun Jin; Xiong Wei; Shulian Wang; Mary K Martel; Ritsuko Komaki; H Helen Liu; Radhe Mohan; Yuhchyau Chen; James D Cox; Zhongxing Liao
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-14       Impact factor: 7.038

7.  Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.

Authors:  Matthias Guckenberger; Rainer J Klement; Larry L Kestin; Andrew J Hope; Jose Belderbos; Maria Werner-Wasik; Di Yan; Jan-Jakob Sonke; Jean-Pierre Bissonnette; Ying Xiao; Inga S Grills
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-11-12       Impact factor: 7.038

8.  Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer.

Authors:  Yvette Seppenwoolde; Katrien De Jaeger; Liesbeth J Boersma; José S A Belderbos; Joos V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-11-01       Impact factor: 7.038

9.  Irradiation of varying volumes of rat lung to same mean lung dose: a little to a lot or a lot to a little?

Authors:  Vladimir A Semenenko; Robert C Molthen; Chunrong Li; Natalya V Morrow; Rongshan Li; Swarajit N Ghosh; Meetha M Medhora; X Allen Li
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-24       Impact factor: 7.038

10.  Damage and morbidity from pneumonitis after irradiation of partial volumes of mouse lung.

Authors:  Z X Liao; E L Travis; S L Tucker
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-07-30       Impact factor: 7.038

View more
  1 in total

1.  Occurrence of pneumonitis following radiotherapy of breast cancer - A prospective study.

Authors:  Danijela Vasiljevic; Christoph Arnold; David Neuman; Katharina Fink; Marina Popovscaia; Irma Kvitsaridze; Meinhard Nevinny-Stickel; Markus Glatzer; Peter Lukas; Thomas Seppi
Journal:  Strahlenther Onkol       Date:  2018-02-15       Impact factor: 3.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.